Quark Biotechnology is a Taiwan-based biotechnology startup that focuses on developing innovative tests using the NextAmp™ Analysis System. Founded in 2012, the company aims to provide precision healthcare solutions tailored to individual genetic profiles. Recognizing the limitations of traditional medical approaches, QuarkBio's products cover a wide range of services including disease prevention, diagnosis, treatment, and prognosis.
The company attracted Series A investment from Recharge Thematic Ventures in December 15, 2020. This funding reflects investor confidence in Quark Bio's potential to revolutionize the healthcare industry with its personalized approach. As QuarkBio continues to demonstrate its commitment to making precision healthcare solutions more accessible, its strategic partnerships and innovative technologies position it as a promising player in the biotechnology sector.